Characterizing Pharmacogenomic‐Guided Medication Use With a Clinical Data Repository
暂无分享,去创建一个
Peter Tarczy-Hornoch | Beth Devine | W. J. Wang | Nathaniel Hendrix | P. C. Mathias | P. Tarczy-Hornoch | B. Devine | K. Keyloun | P. Mathias | Katelyn R. Keyloun | M. Khelifi | N. Hendrix | M. Khelifi
[1] Christopher G Chute,et al. Preemptive genotyping for personalized medicine: design of the right drug, right dose, right time-using genomic data to individualize treatment protocol. , 2014, Mayo Clinic proceedings.
[2] Amie C O'Donoghue,et al. Primary Care Physicians' Use of FDA-Approved Prescription Drug Labels , 2014, The Journal of the American Board of Family Medicine.
[3] Melissa A. Basford,et al. Optimizing Drug Outcomes Through Pharmacogenetics: A Case for Preemptive Genotyping , 2012, Clinical pharmacology and therapeutics.
[4] Shashi Amur,et al. Pharmacogenomic Biomarker Information in Drug Labels Approved by the United States Food and Drug Administration: Prevalence of Related Drug Use , 2008, Pharmacotherapy.
[5] R. Verbrugge,et al. Adoption of Pharmacogenomic Testing by US Physicians: Results of a Nationwide Survey , 2012, Clinical pharmacology and therapeutics.
[6] W. Galanter,et al. Feasibility of Implementing a Comprehensive Warfarin Pharmacogenetics Service , 2013, Pharmacotherapy.
[7] Teri E Klein,et al. Preemptive clinical pharmacogenetics implementation: current programs in five US medical centers. , 2015, Annual review of pharmacology and toxicology.
[8] Russ B. Altman,et al. Pharmacogenomics and bioinformatics: PharmGKB. , 2010, Pharmacogenomics.
[9] M. Relling,et al. Preemptive Clinical Pharmacogenetics Implementation: Current programs in five United States medical centers , 2015 .
[10] Soma Das,et al. Adoption of a clinical pharmacogenomics implementation program during outpatient care–initial results of the University of Chicago “1,200 Patients Project” , 2014, American journal of medical genetics. Part C, Seminars in medical genetics.
[11] Erica A. Bowton,et al. Clinically actionable genotypes among 10,000 patients with preemptive pharmacogenomic testing , 2013, Clinical pharmacology and therapeutics.
[12] M. Relling,et al. Development and use of active clinical decision support for preemptive pharmacogenomics , 2013, Journal of the American Medical Informatics Association : JAMIA.
[13] Ching-Hon Pui,et al. PG4KDS: A model for the clinical implementation of pre‐emptive pharmacogenetics , 2014, American journal of medical genetics. Part C, Seminars in medical genetics.
[14] R. Porcher,et al. Guidance for pharmacogenomic biomarker testing in labels of FDA-approved drugs , 2014, Genetics in Medicine.
[15] E. Clayton,et al. Operational Implementation of Prospective Genotyping for Personalized Medicine: The Design of the Vanderbilt PREDICT Project , 2012, Clinical pharmacology and therapeutics.
[16] Daniel J. Vreeman,et al. Supporting interoperability of genetic data with LOINC , 2015, J. Am. Medical Informatics Assoc..
[17] W. Rogers. Regression standard errors in clustered samples , 1994 .
[18] F. Frueh,et al. Physician Awareness and Utilization of Food and Drug Administration (FDA)-Approved Labeling for Pharmacogenomic Testing Information , 2013, Journal of personalized medicine.